Novavax Inc., a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, has signed a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Company’s COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community.    “This arrangement with the Australian Government reflects the importance of the ongoing clinical development of NVAX-CoV2373, and will ensure that the citizens of Australia will have a...